Cargando…

Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B

OBJECTIVE: Extreme drug-resistant Pseudomonas aeruginosa (XDR-PA) with decreased susceptibility to polymyxin B (PB) has emerged in Singapore, causing infections in immunocompromised hosts. Combination therapy may be the only viable therapeutic option until new antibiotics become available. The objec...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Tze-Peng, Lee, Winnie, Tan, Thean-Yen, Sasikala, Suranthran, Teo, Jocelyn, Hsu, Li-Yang, Tan, Thuan-Tong, Syahidah, Nur, Kwa, Andrea L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230594/
https://www.ncbi.nlm.nih.gov/pubmed/22162759
http://dx.doi.org/10.1371/journal.pone.0028177
_version_ 1782218075941109760
author Lim, Tze-Peng
Lee, Winnie
Tan, Thean-Yen
Sasikala, Suranthran
Teo, Jocelyn
Hsu, Li-Yang
Tan, Thuan-Tong
Syahidah, Nur
Kwa, Andrea L.
author_facet Lim, Tze-Peng
Lee, Winnie
Tan, Thean-Yen
Sasikala, Suranthran
Teo, Jocelyn
Hsu, Li-Yang
Tan, Thuan-Tong
Syahidah, Nur
Kwa, Andrea L.
author_sort Lim, Tze-Peng
collection PubMed
description OBJECTIVE: Extreme drug-resistant Pseudomonas aeruginosa (XDR-PA) with decreased susceptibility to polymyxin B (PB) has emerged in Singapore, causing infections in immunocompromised hosts. Combination therapy may be the only viable therapeutic option until new antibiotics become available. The objective of this study is to assess the in vitro activity of various antibiotics against local XDR-PA isolates. METHODS: PA isolates from all public hospitals in Singapore were systematically collected between 2006 and 2007. MICs were determined according to CLSI guidelines. All XDR-PA isolates identified were genotyped using a PCR-based method. Time-kill studies (TKS) were performed with approximately 10(5) CFU/ml at baseline using clinically achievable unbound concentrations of amikacin (A), levofloxacin (L), meropenem (M), rifampicin (R) and PB alone and in combination. Bactericidal activity (primary endpoint) was defined as a ≥3 log(10) CFU/ml decrease in the colony count from the initial inoculum at 24 hours. RESULTS: 22 clinical XDR-PA isolates with PB MIC 2–16 µg/ml were collected. From clonal typing, 5 clonal groups were identified and nine isolates exhibited clonal diversity. In TKS, meropenem plus PB, amikacin plus meropenem, amikacin plus rifampicin, amikacin plus PB exhibited bactericidal activity in 8/22, 3/22, 1/22 and 6/22 isolates at 24 hours respectively. Against the remaining ten isolates where none of the dual-drug combination achieved bactericidal activity against, only the triple-antibiotic combinations of ARP and AMP achieved bactericidal activity against 7/10 and 6/10 isolates respectively. CONCLUSION: Bactericidal activity with sustained killing effect of ≥99.9% is critical for eradicating XDR-PA infections, especially in immunocompromised hosts. These findings underscore the difficulty of developing combination therapeutic options against XDR-PA, demonstrating that at least 3 antibiotics are required in combination and that efficacy is strain dependant.
format Online
Article
Text
id pubmed-3230594
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32305942011-12-08 Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B Lim, Tze-Peng Lee, Winnie Tan, Thean-Yen Sasikala, Suranthran Teo, Jocelyn Hsu, Li-Yang Tan, Thuan-Tong Syahidah, Nur Kwa, Andrea L. PLoS One Research Article OBJECTIVE: Extreme drug-resistant Pseudomonas aeruginosa (XDR-PA) with decreased susceptibility to polymyxin B (PB) has emerged in Singapore, causing infections in immunocompromised hosts. Combination therapy may be the only viable therapeutic option until new antibiotics become available. The objective of this study is to assess the in vitro activity of various antibiotics against local XDR-PA isolates. METHODS: PA isolates from all public hospitals in Singapore were systematically collected between 2006 and 2007. MICs were determined according to CLSI guidelines. All XDR-PA isolates identified were genotyped using a PCR-based method. Time-kill studies (TKS) were performed with approximately 10(5) CFU/ml at baseline using clinically achievable unbound concentrations of amikacin (A), levofloxacin (L), meropenem (M), rifampicin (R) and PB alone and in combination. Bactericidal activity (primary endpoint) was defined as a ≥3 log(10) CFU/ml decrease in the colony count from the initial inoculum at 24 hours. RESULTS: 22 clinical XDR-PA isolates with PB MIC 2–16 µg/ml were collected. From clonal typing, 5 clonal groups were identified and nine isolates exhibited clonal diversity. In TKS, meropenem plus PB, amikacin plus meropenem, amikacin plus rifampicin, amikacin plus PB exhibited bactericidal activity in 8/22, 3/22, 1/22 and 6/22 isolates at 24 hours respectively. Against the remaining ten isolates where none of the dual-drug combination achieved bactericidal activity against, only the triple-antibiotic combinations of ARP and AMP achieved bactericidal activity against 7/10 and 6/10 isolates respectively. CONCLUSION: Bactericidal activity with sustained killing effect of ≥99.9% is critical for eradicating XDR-PA infections, especially in immunocompromised hosts. These findings underscore the difficulty of developing combination therapeutic options against XDR-PA, demonstrating that at least 3 antibiotics are required in combination and that efficacy is strain dependant. Public Library of Science 2011-12-05 /pmc/articles/PMC3230594/ /pubmed/22162759 http://dx.doi.org/10.1371/journal.pone.0028177 Text en Lim et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Lim, Tze-Peng
Lee, Winnie
Tan, Thean-Yen
Sasikala, Suranthran
Teo, Jocelyn
Hsu, Li-Yang
Tan, Thuan-Tong
Syahidah, Nur
Kwa, Andrea L.
Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B
title Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B
title_full Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B
title_fullStr Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B
title_full_unstemmed Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B
title_short Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B
title_sort effective antibiotics in combination against extreme drug-resistant pseudomonas aeruginosa with decreased susceptibility to polymyxin b
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230594/
https://www.ncbi.nlm.nih.gov/pubmed/22162759
http://dx.doi.org/10.1371/journal.pone.0028177
work_keys_str_mv AT limtzepeng effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb
AT leewinnie effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb
AT tantheanyen effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb
AT sasikalasuranthran effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb
AT teojocelyn effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb
AT hsuliyang effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb
AT tanthuantong effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb
AT syahidahnur effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb
AT kwaandreal effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb